/
PODD
$152.25-$5.49 (-3.48%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$11.0B
69M shares
52-week range
$138.79 – $354.88
6% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-126.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $563.8M | $738.2M | $904.4M | $1.10B | $1.31B | $1.70B | $2.07B | $2.71B |
| Cost of revenue | $193.7M | $257.9M | $322.1M | $346.7M | $499.7M | $537.2M | $625.9M | $768.2M |
| Gross profit | $370.2M | $480.3M | $582.3M | $752.1M | $805.6M | $1.16B | $1.45B | $1.94B |
| Gross margin | 65.7% | 65.1% | 64.4% | 68.4% | 61.7% | 68.3% | 69.8% | 71.6% |
| R&D | $88.6M | $132.3M | $146.8M | $160.1M | $180.2M | $205.0M | $219.6M | $301.1M |
| Operating income | $27.4M | $50.0M | $51.5M | $126.0M | $37.6M | $220.0M | $308.9M | $473.8M |
| EBITDA | $47.1M | $74.2M | $110.3M | $139.6M | $109.0M | $323.6M | $423.7M | $532.3M |
| Net income | $3.3M | $11.6M | $6.8M | $16.8M | $4.6M | $206.3M | $418.3M | $247.1M |
| Net margin | 0.6% | 1.6% | 0.8% | 1.5% | 0.4% | 12.2% | 20.2% | 9.1% |
| EPS (diluted) | 0.05 | 0.19 | 0.10 | 0.25 | 0.07 | 2.94 | 5.78 | 3.48 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3.3B | $6.48 | $6.39–$6.58 | 13 |
| 2027 | $4.0B | $8.11 | $7.47–$8.46 | 14 |
| 2028 | $4.7B | $10.21 | $9.61–$10.55 | 7 |
| 2029 | $5.5B | $12.64 | $11.97–$12.93 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
www.insulet.com- Employees
- 5,400
- IPO / List date
- May 15, 2007
- HQ
- ACTON, MA
Held by traders on TradeandTell
No one on the platform currently holds PODD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 426,003 | $89.4M |
| Bridgewater Associatesas of 2026-03-31 | 35,336 | $7.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PODD yet.
